Blinatumomab for Named Patient Import

Blinatumomab for Indian Patients

Blinatumomab is a highly advanced immunotherapy medication, approved by the US FDA, for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL). Blinatumomab is recommended by Hematologists in India. Patients eligible for Bone Marrow Transplantation are often considered to be the major beneficiary group. Manufactured and promoted by Amgen, Blinatumomab is known by its trade name - Blincyto.

Blinatumomab or Blincyto in India is not available through regular domestic channels. The reason being Blincyto in India is yet to be registered. However, patients in India can very well access and procure Blinatumomab through the legal channels of import.  Blincyto is usually available as 38.5mcg vials. Blinatumomab can be procured by the Indian patients by securing Named Patient Import permit, issued strictly for personal use.

Blinatumomab in India? Seek expert assistance.

If your treating physician has recommended Blinatumomab or Blincyto, usually you are expected to fast track the procurement process. You can take our expert assistance in getting in touch with the most authentic and reliable global sources. The sources we connect you with are duly licensed and have the prior experience of supplying Blinatumomab in India. You also need not worry about the complex documentation procedures. We will provide you with end to end support that makes your entire sourcing experience simple and hassle free.

Reach us by emailing us to nhs@noelbiotech.com or calling us on + 91 9677010046 / + 91 9929277766.